Pay in 4 interest-free payments of $6.53 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
In the FLOW trial, titration up to 1 mg was performed when clinically tolerated
Furthermore, regarding the primary endpoint, the diminished number of cardiovascular events implies an absolute reduction of only 1.5 per 100 people in a high cardiovascular risk cohort, taking Wegovy for more than three years
link to editorial: Very informative editorial ME
Finally, while the primary outcomes we selected (weight loss and HbA1c) were consistent with clinical trial endpoints, they are limited in their ability to analyze early and true physiological impacts of GLP-1s such as changes to visceral and subcutaneous fat
US$ 23.86
US$ 24.72
US$ 27.53
